Full-Time

Senior Talent Acquisition Partner

Scientific

Iambic Therapeutics

Iambic Therapeutics

51-200 employees

AI-driven discovery for oncology and neurology

Compensation Overview

$55 - $85/hr

San Diego, CA, USA

Hybrid

Hybrid on-site schedule at the San Diego headquarters.

Bachelor's

Category
People & HR (1)
Required Skills
Applicant Tracking Software (ATS)
Computer Networking

Get referred to Iambic Therapeutics

See people who can refer or advise you

Requirements
  • A Bachelor's degree in Business Administration, Human Resources, or a related field, or equivalent experience.
  • At least 5 years of full-cycle recruiting experience.
  • Experience recruiting for scientific and pre-clinical roles in a fast-paced environment.
  • Ability to manage multiple searches simultaneously while maintaining strong candidate and hiring manager relationships.
  • Strong consultative partnership skills with the ability to influence and guide hiring managers.
  • Excellent verbal and written communication skills with the ability to manage sensitive and confidential information.
  • Solid understanding of recruiting compliance standards and best practices.
  • Experience using LinkedIn Recruiter.
Responsibilities
  • Manage full-cycle recruiting for assigned roles, including intake meetings, sourcing, screening, interview coordination, offer support, and closing candidates.
  • Drive efficient hiring processes with a focus on speed, quality, and candidate experience.
  • Partner with hiring managers to understand role requirements, hiring priorities, and candidate profiles.
  • Execute sourcing and recruiting strategies aligned with business needs and approved hiring plans.
  • Provide regular updates and maintain proactive communication with hiring managers and Human Resources throughout the recruiting process.
  • Build and maintain pipelines of qualified candidates, including active and passive talent.
  • Use recruiting tools and resources, including LinkedIn Recruiter, referrals, networking, and targeted outreach, to identify qualified talent.
  • Support offer development and negotiation in partnership with Human Resources and hiring managers, following established guidelines.
  • Maintain accurate and compliant candidate records in the Ashby applicant tracking system.
  • Ensure recruiting activities align with internal processes and relevant compliance standards.
  • Deliver a professional and consistent candidate experience throughout the recruiting lifecycle.
  • Represent the company positively in candidate, vendor, and external interactions.
Desired Qualifications
  • Experience recruiting in biotechnology, life sciences, or pharmaceutical environments.
  • Experience using the Ashby applicant tracking system.
  • Familiarity with talent market intelligence tools.

Iambic Therapeutics develops therapeutics using an AI-driven discovery platform, focusing on oncology and neurological diseases in clinical-stage programs. The platform combines advanced AI models with automated experiments to predict molecular properties faster and with less data, speeding identification and optimization of drug candidates. It differentiates itself by maintaining an in-house pipeline alongside strategic pharmaceutical partnerships to advance programs and earn milestones and royalties. The goal is to bring new therapies to patients by accelerating discovery and development through AI and automation.

Company Size

51-200

Company Stage

Late Stage VC

Total Funding

$303M

Headquarters

San Diego, California

Founded

2019

Get referred to Iambic Therapeutics

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Takeda’s February 9, 2026 deal could exceed $1.7 billion with royalties.
  • Iambic raised over $100 million on November 10, 2025, then $27.8 million in April 2026.
  • IAM1363 entered 53 sites by June 4, 2026, expanding execution momentum.

What critics are saying

  • IAM1363’s Phase 1 completion stretches to December 2028, delaying clear value inflection.
  • Takeda and Jazz partnership economics remain undisclosed, leaving revenue quality opaque.
  • A clinical miss in HER2 programs would puncture Iambic’s platform-validation story.

What makes Iambic Therapeutics unique

  • Tom Miller’s NeuralPLexer and wet-lab loop accelerated Takeda discovery on February 9, 2026.
  • IAM1363 is brain-penetrant and HER2-selective, spanning wild-type and mutant HER2 cancers.
  • Iambic pairs clinical programs with platform deals, unlike single-asset AI-biotech peers.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

401(k) Company Match

Unlimited Paid Time Off

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

-1%

2 year growth

-3%
Intelligence360 News
Dec 3rd, 2025
Iambic Therapeutics raises $125M in new funding

Iambic Therapeutics has filed a notice with the US Securities and Exchange Commission for an exempt offering to raise $125 million in new funding. The filing was made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act, which allows companies to sell securities without registration under the Securities Act of 1933. Federal securities law requires such notices to be filed within 15 days after the first sale of securities in the offering. No additional details about the funding round, including investors or valuation, were disclosed in the filing.

Iambic Therapeutics
Nov 11th, 2025
Iambic Raises Over $100 Million in an Oversubscribed Round to Advance its Portfolio of AI-Discovered Therapeutics and Leading Platform Technologies

San Diego, CA – Nov. 10, 2025 – Iambic, a clinical-stage life science and technology company developing novel medicines using its AI-driven discovery and development platform, today announced raising over $100 million in an oversubscribed financing round with balanced support from new and existing investors, including Abingworth, Alexandria Venture Investments, Alumni Ventures, ARK, Ascenta, Catalio, Everbright Biofund, Freeflow Ventures, Illumina Ventures, Mubadala, Pegasus Tech Ventures, Qatar Investment Authority, Regeneron Ventures, Sequoia, Tao Capital Partners, Terra Magnum Capital Partners, Wilson Sonsini Goodrich & Rosati, and others.

Endpoints News
Nov 10th, 2025
Iambic Therapeutics raises $100M funding

Iambic Therapeutics has secured over $100 million in a new funding round, as revealed by CEO Tom Miller. The investment comes from ARK and Regeneron, highlighting significant financial backing for the San Diego-based biotech company.

EntArabi
Jun 20th, 2024
Iambic Therapeutics raises $50M in Series B

Iambic Therapeutics, a US-based biotech company, raised $50 million in an expanded Series B funding round led by Mubadala Capital. The round included Qatar Investment Authority, Exor Ventures, and existing investors like Abingworth, Illumina Ventures, Nexus Venture Partners, Coatue, and Tao Capital Partners. This funding is part of a previous $100 million Series B round closed in October 2023. The funds will be used to advance Iambic's clinical and preclinical programs.

Pharmaceutical Business Review
Jun 19th, 2024
Iambic secures $50m to bolster clinical oncology programme pipeline

Iambic Therapeutics has secured $50m in its Series B extension financing round to bolster its pipeline comprising clinical oncology programmes.